Journal of Drug Delivery

Nanotechnologies in Cancer


Publishing date
22 Mar 2013
Status
Published
Submission deadline
02 Nov 2012

1Department of Pharmaceutical and Toxicological Chemistry, University Federico II of Naples, Naples, Italy

2Department of Biochemistry and Biophysics, Second University of Naples, Naples, Italy

3Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy

4Department of Pharmaceutical Sciences, Midwestern University, Glendale, AZ, USA


Nanotechnologies in Cancer

Description

Cancer is today the major cause of morbidity and mortality in western and industrialized countries. Anticancer drugs often need to be used at high doses in order to achieve a significant antitumor activity and can induce damaging effects on normal tissues since they are not specific for cancer cells. Also new target-based agents, raised against molecular targets putatively altered in cancer cells, are not strictly specific for tumour tissues. In fact, their targets are often involved in the maintenance of the homeostasis of several normal tissues. The emergence of nanomedicine science has opened a novel scenario in the administration modalities of both conventional cytotoxic drugs and target-based agents with the possibility to improve their efficacy and to reduce their side effects. This can be achieved by the nanotechnology-mediated delivery of anticancer agents in tumor tissues sparing healthy ones. Nanotechnologies can also allow delivery in tumor tissues of new biopharmaceutical agents based on nucleic acids, such as plasmids, antisense oligonucleotides, decoy oligonucleotides, small interfering RNAs, and microRNAs.

Presently, lipid-based nanovectors, and in details liposomes, are the only nanotechnological formulations already used in the clinical practice, while polymeric nanovectors are in advanced phase of clinical development in several countries. Moreover, a growing number of research groups are working to expand the applications of nanotechnological platforms in cancer from drug delivery to diagnostics. Finally, continuous efforts by investigators are aimed to optimize the performance of nanovectors in order to increase the selectivity toward target tissues and/or cells.

We invite researchers to contribute to this special issue with original articles or reviews to cover all the aspects of the nanotechnologies in cancer therapy. In particular, potential topics include, but are not limited to:

  • New biomaterials and/or nanovectors for drug delivery and/or diagnostics
  • New applications of biomaterials and/or nanovectors for drug delivery and/or diagnostics
  • Polymeric conjugates for drug delivery and/or diagnostics
  • Nanotechnologies for gene/oligonucleotide delivery
  • Physicochemical evaluation of nanocarriers in biological environments
  • Nanovehicle strategies for improvement of ADME of therapeutic molecules
  • Properties affecting tumor targeting of nanocarriers
  • Preclinical evidence for usefulness of Nanotechnologies in cancer
  • Clinical studies with Nanotechnology-based products
  • Impact of Nanotechnologies on clinical practice

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/jdd/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2013
  • - Article ID 604293
  • - Editorial

Nanotechnologies in Cancer

Giuseppe De Rosa | Michele Caraglia | ... | Tamer Elbayoumi
  • Special Issue
  • - Volume 2013
  • - Article ID 905091
  • - Review Article

Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?

Iole Cucinotto | Lucia Fiorillo | ... | Pierosandro Tagliaferri
  • Special Issue
  • - Volume 2013
  • - Article ID 456409
  • - Review Article

Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review

Juan Lao | Julia Madani | ... | Antonio Antón Torres
  • Special Issue
  • - Volume 2013
  • - Article ID 897348
  • - Review Article

Gene Therapy for Advanced Melanoma: Selective Targeting and Therapeutic Nucleic Acids

Joana R. Viola | Diana F. Rafael | ... | Manfred Ogris
  • Special Issue
  • - Volume 2013
  • - Article ID 898146
  • - Review Article

Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer

Carmela Pisano | Sabrina Chiara Cecere | ... | Sandro Pignata
  • Special Issue
  • - Volume 2013
  • - Article ID 705265
  • - Review Article

Recent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor Targeting

Federico Perche | Vladimir P. Torchilin
  • Special Issue
  • - Volume 2013
  • - Article ID 860780
  • - Review Article

Lipid-Based Nanovectors for Targeting of CD44-Overexpressing Tumor Cells

Silvia Arpicco | Giuseppe De Rosa | Elias Fattal
  • Special Issue
  • - Volume 2013
  • - Article ID 374252
  • - Review Article

Stealth Properties to Improve Therapeutic Efficacy of Drug Nanocarriers

Stefano Salmaso | Paolo Caliceti
  • Special Issue
  • - Volume 2013
  • - Article ID 637976
  • - Review Article

Bisphosphonates and Cancer: What Opportunities from Nanotechnology?

Giuseppe De Rosa | Gabriella Misso | ... | Michele Caraglia
  • Special Issue
  • - Volume 2013
  • - Article ID 147325
  • - Review Article

Neoplastic Meningitis from Solid Tumors: A Prospective Clinical Study in Lombardia and a Literature Review on Therapeutic Approaches

A. Silvani | M. Caroli | ... | A. Salmaggi

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.